With the cell line market in its initial stages of development, a lot of companies are working on the selection of right gene targets and cell lines for its expansion.
One such company is ASC which has gained a reputation for successfully solving the challenges related to these knock-in and knock-out cell line development.
Recently, Abcam, a leading supplier of research tools has announced its expansion in the edited cell line market and purchased gene editing and oncology portfolio from the ASC.
The transaction basically includes the AccuRef reference material product line that uses the ASC gene-edited cell lines to produce biologically-relevant quality control and reference standards for cancer genes.
Abcam has also announced to expand the ASC platform to become its discovery engine for the development of novel edited cell lines and building a range of knock-out cell lines.
These ready-made knock-out cell lines by Abcam will play an important role in studying and understanding disease models and biological pathways.
3 Key Points
“Following our strategic decision to focus on stem cell and derivative service and products for both research and therapeutic applications, we are pleased to be transitioning our oncology-focused services and products to the global team at Abcam.”- Ruby Tsai, co-founder, and CSO of Applied StemCell.
#Pharmaceutical, #Healthcare, #DigitalHealth
P.S. Want to learn more about gene editing and cancer? Always stay informed by getting summarized articles straight to your inbox for FREE. Click here to learn more.